Harvard Pilgrim Health Care Institute | @HarvardMed affiliate. Improving health care delivery and population health.

Boston, MA
Joined December 2017
It is our pleasure to present the 2020 @DeptPopMed Annual Report, highlighting our #COVID19 & #healthdisparities research, findings in key areas from #comparativeeffectiveness to #healthpolicy to #therapeutics, work growing our teaching programs, & more: ow.ly/28p150FCpQF
0
6
2
11
Department of Population Medicine retweeted
Appreciative of great mentors @mfhivert @EmilyOkenMD @elsiemt and team for the opportunity to 🔎 central adiposity gain and cardiometabolic health in adolescence in Project Viva
New Article! "Associations of #midchildhood to early adolescence #central #adiposity #gain with #cardiometabolic health in early adolescence" Co authored by @PROMoTeR_DPM Member, @mfhivert is published in buff.ly/39Lwicc buff.ly/39Lwicc
0
1
0
2
Department of Population Medicine retweeted
Take a look at the visual abstract below highlighting the findings from this study! To read the full study published in @JAMANetworkOpen click here: buff.ly/2Zl9b6L @PROMoTeR_DPM @DeptPopMed #GeneticTesting #PediatricCancer
0
1
0
2
Show this thread
Seeking a mid-career/sr. researcher to lead our @HealthPolicyDPM division! @DeptPopMed is home to rich data resources, & has numerous strong local & national connections that amplify the opportunities for/impact of our research. #HealthPolicyTwitter ow.ly/N3PY50GuA79
New opportunity - @DeptPopMed seeks a mid-career/senior researcher to lead its @HealthPolicyDPM division. ow.ly/N3PY50GuA79 See more opportunities in health research on our job board! hcsrn.org/en/JOBS/
0
2
1
5
Department of Population Medicine retweeted
Come join us! It’s a great opportunity to do health policy work in an academic department that’s also affiliated with a health plan
#NowHiring: @DeptPopMed seeks a faculty member to lead its @HealthPolicyDPM division! Join us: participate in collaborative #healthpolicy research (esp in the areas of health insurance & equity) & contribute to an equitable, diverse scholarly environment. ow.ly/O5aR50Gua6U
0
4
1
11
#NowHiring: @DeptPopMed seeks a faculty member to lead its @HealthPolicyDPM division! Join us: participate in collaborative #healthpolicy research (esp in the areas of health insurance & equity) & contribute to an equitable, diverse scholarly environment. ow.ly/O5aR50Gua6U
1
6
3
15
Department of Population Medicine retweeted
New study published in @JAMANetworkOpen co authored by @CHeRP_DPM members, @kdchrist & @Asthma3Ways highlights findings from the Precision Medicine Policy and Treatment ( #PreEMPT) Model, an @NIH/@NICHD_NIH funded study lead by @Asthma3Ways!
1
2
0
5
Show this thread
Department of Population Medicine retweeted
New @RWJF-supported webinar from AcademyHealth and @SSNScholars seeks to help researchers build knowledge and skills to conduct community-engaged research bit.ly/3p32BfJ
0
1
0
0
Bring your lunch and join us for a @DeptPopMed Brown Bag seminar via Zoom this Thursday, 10/21 at 12pm! @jasonpblock presents "COVID-19 Surveillance in a National Research Network". For details: ow.ly/vAFf50GtfdT #COVID19
0
0
0
4
Department of Population Medicine retweeted
On Oct. 20, join @NIH_ORWH for a conference to address NIH efforts related to women’s health research. Panels will cover maternal morbidity and mortality, chronic debilitating conditions in women, and the cervical cancer survival rate. bit.ly/3jdzj9H #HealthOfWomen2021
0
10
2
12
Little is known about using #genetic #testing on siblings of children w/mutations. New study shows sibling #cascade testing can prevent #cancer deaths. Do its benefits outweigh the $/harms? The @PROMoTeR_DPM #PreEMPT team dives deeper in @JAMANetworkOpen ow.ly/PMe950Gthit
1
2
2
8
“Our findings suggest that cancer drugs without documented overall survival or quality of life benefits are adopted in the health system and account for substantial spending,” says @LSEHealthPolicy’s Huseyin Naci (@HuseyinNaci2), a key collaborator on both studies. 5/12
1
1
0
1
Study 2: Estimated #Medicare spending on the 10 accelerated approval cancer drugs reevaluated by the FDA and found to lack overall survival benefit. 6/12 ow.ly/JIgD50Gtd9r
1
0
0
1
The accelerated approval pathway is intended to offer early access to potentially effective drugs. Drug manufacturers must confirm overall survival benefit post-approval. As the study authors found, much $ is spent on drugs without overall survival benefit. Just how much? 7/12
1
0
0
0
They estimate Medicare Parts B & D spent @ least $569 million cumulatively in 2017-19 on 10 cancer drugs w/o overal survival benefit following accelerated approval. 8/12
1
0
0
0
$224 million of that was on drugs that were later a) voluntarily w/drawn by the manufacturer or b) recommended by the FDA for w/drawal. 9/12
1
0
0
0
“Unless the accelerated approval pathway is reformed, significant spending on drugs with no proven clinical benefit will likely continue,” says lead author of the #Medicare based study, @HealthPolicyDPM research fellow Mahnum Shahzad (@MahnumShahzad). 10/12
1
0
0
0
Multiple factors - drug regulatory, pricing, and reimbursement policies - likely contribute to wasteful healthcare spending (#FinancialPollution) in the US. But what’s the fix? 11/12
1
0
0
0
“Policy approaches should consider the health system context in which approval regulations, pricing decisions, and coverage mandates for cancer drugs intersect,” says sr. author of both studies, @DeptPopMed's Anita Wagner. ow.ly/QVZP50Gtdu3 /end
0
0
0
0
Show this thread